A new Medicare pilot program aims to simplify access to GLP-1 medications by offering some seniors a capped monthly cost of $50, potentially making these weight-loss and diabetes treatments more affordable. However, the discount will not extend to individuals with the most severe conditions, leaving a significant portion of eligible patients facing higher out-of-pocket expenses. The initiative reflects broader efforts to address prescription drug costs while raising questions about equity in coverage for different patient groups. Details on eligibility and long-term sustainability remain unclear as the program rolls out.
Medicare launched a pilot program that could streamline the process to get GLP-1s, with some seniors paying just $50 a month. But many people with the most serious illnesses won't get that discount.
